NAGE vs TRLV
Niagen Bioscience, Inc. and Trulieve Cannabis Corp., side by side — 7 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | NAGE | TRLV |
|---|---|---|
| Revenue | $129.4M | $1.2B |
| Net income | $17.4M | $-122.2M |
| Gross margin | 64.3% | 60.2% |
| Net margin | 13.4% | −10.3% |
| Return on equity | 28.3% | — |
| Diluted EPS | $0.20 | −$0.58 |
| Dividend / share | — | — |
| Payout ratio | — | — |
| Free cash flow | $-21.2M | $228.6M |
| Equity | $76.5M | — |
| Net debt / equity | — | — |
| Current ratio | 4.86× | 4.43× |
| Revenue CAGR 5y | 16.9% | 17.8% |
| Profit CAGR 5y | — | — |
TRLV bills 9.1× the revenue of NAGE, and TRLV closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
7 years side by side
| Fiscal year | NAGE | TRLV |
|---|---|---|
| FY2025 | $129.4M | $1.2B |
| FY2024 | $99.6M | $1.2B |
| FY2023 | $83.6M | $1.1B |
| FY2022 | $72.0M | $1.2B |
| FY2021 | $67.4M | $931.9M |
| FY2020 | $59.3M | $521.5M |
| FY2019 | $46.3M | $252.8M |
Net income by year
Bottom line
| Fiscal year | NAGE | TRLV |
|---|---|---|
| FY2025 | $17.4M | $-122.2M |
| FY2024 | $8.6M | $-160.6M |
| FY2023 | $-4.9M | $-533.1M |
| FY2022 | $-16.5M | $-252.7M |
| FY2021 | $-27.1M | $17.4M |
| FY2020 | $-19.9M | $63.0M |
| FY2019 | $-32.1M | $53.1M |
Advertisement
AdSense · Rectangle 336×280
More in this industry